Chengdu, China, May 1, 2025 -- HUITAI Biomedicine (HUITAI), a clinical stage biotechnology company specialized in the development and commercialization of anti-fibrosis peptide novel medicine, today announced that HUITAI’s CEO, Mr. Yijun Wei, Bruce, will participate in an oral presentation during the ILD/Fibrosis Session at the Respiration Innovation Summit 2025 in San Francisco.

▸Title: HTPEP-001, A Novel Inhaled Peptide for Pulmonary Fibrosis Treatment, Demonstrated High Safety and Tolerability Profile in Phase I Trial

▸Presenter: Mr. Yijun Wei, Bruce, CEO of Chengdu Huitai Biomedicine Co., Ltd

▸Time: 11:30 a.m. Pacific Time, Saturday, May 17, 2025

▸Venue: San Francisco Marriott Marquis, Yerba Buena Ballroom (Lower B2 Level)

For more information about RIS 2025, please visit:  https://conference.thoracic.org/program/ris/agenda.php

*For more information about Huitai, please visit:  http://www.cdhuitai.cn/

About HUITAI Biomedicine

Chengdu HUITAI Biomedicine is a clinical-stage biotech company focused on developing anti-fibrotic peptides through novel TGF-β technology. Unlike conventional TGF-β inhibitors that target integrins or TGF-β directly, HUITAI's lead asset, HTPEP-001, selectively antagonizes the interaction between TSP-1 and CD36 to block TGF-β1 activation.

This mechanism preserves antifibrotic efficacy while markedly expanding the therapeutic safety window.

Inhaled HTPEP-001 has demonstrated significant efficacy in reducing active TGF-β1 and alleviating lung fibrosis in preclinical animal models, with a safety margin exceeding 50-fold. The Phase I clinical trial confirmed its excellent safety and tolerability profile in humans, positioning inhaled HTPEP-001 as a promising therapeutic candidate for PF-ILD and IPF treatment.